231
Views
3
CrossRef citations to date
0
Altmetric
Drug Profile

Acute bacterial skin and skin structure infections in pediatric patients: potential role of dalbavancin

ORCID Icon, ORCID Icon & ORCID Icon
Pages 329-341 | Received 28 Nov 2022, Accepted 16 Feb 2023, Published online: 27 Feb 2023

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Mingming Li, Xia Zhu, Zhiqiang Cao, Lingyun Du, Jingjing Wei & Chunhong Zhang. (2023) Fire Needle Combined Topical Mupirocin for the Treatment of Simple Skin Abscesses in Pediatric Patients: A Case Series. Infection and Drug Resistance 16, pages 3683-3692.
Read now
Alessandra Oliva, Francesco Giuseppe De Rosa, Malgorzata Mikulska, Federico Pea, Maurizio Sanguinetti, Carlo Tascini & Mario Venditti. (2023) Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin. Expert Review of Anti-infective Therapy 21:9, pages 957-975.
Read now
Alessandra Oliva, Sergio Carbonara, Vito Cianci, Massimo Crapis, Enea Gino Di Domenico, Marco Falcone, Gioacchino Galardo, Emanuele Durante-Mangoni & Mario Venditti. (2023) Direct or early Discharge of Acute Bacterial Skin and Skin Structure Infection patients from the Emergency Department/Unit: place in therapy of dalbavancin. Expert Review of Anti-infective Therapy 21:7, pages 703-721.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.